Last reviewed · How we verify
Placebo Azathioprine
Azathioprine is a prodrug that is converted to 6-mercaptopurine, which inhibits purine synthesis and suppresses T-cell and B-cell proliferation.
Azathioprine is a prodrug that is converted to 6-mercaptopurine, which inhibits purine synthesis and suppresses T-cell and B-cell proliferation. Used for Prevention of organ rejection in transplant recipients, Autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.
At a glance
| Generic name | Placebo Azathioprine |
|---|---|
| Sponsor | Medical University of Warsaw |
| Drug class | Immunosuppressant / Purine antagonist |
| Target | Inosine monophosphate dehydrogenase (IMPDH), purine synthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Azathioprine acts as an immunosuppressant by interfering with nucleotide metabolism, particularly purine synthesis. After hepatic conversion to 6-mercaptopurine and further metabolism, it inhibits the proliferation of lymphocytes, reducing both cellular and humoral immune responses. This makes it effective in preventing organ rejection and treating autoimmune conditions.
Approved indications
- Prevention of organ rejection in transplant recipients
- Autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease
Common side effects
- Bone marrow suppression / leukopenia
- Nausea and vomiting
- Hepatotoxicity
- Infection
- Pancreatitis
- Alopecia
Key clinical trials
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (PHASE2)
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. (PHASE3)
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) (PHASE3)
- Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) (PHASE3)
- Baricitinib in Patients With Relapsing or naïve Dermatomyositis (PHASE3)
- Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Azathioprine CI brief — competitive landscape report
- Placebo Azathioprine updates RSS · CI watch RSS
- Medical University of Warsaw portfolio CI